RXST Strangle Strategy
RXST (RxSight, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST (RxSight, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $229.8M, a beta of 1.24 versus the broader market, a 52-week range of 5.3-16.74, average daily share volume of 766K, a public-listing history dating back to 2021, approximately 498 full-time employees. These structural characteristics shape how RXST stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.24 places RXST roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on RXST?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current RXST snapshot
As of May 15, 2026, spot at $5.62, ATM IV 231.90%, IV rank 50.61%, expected move 66.48%. The strangle on RXST below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on RXST specifically: RXST IV at 231.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 66.48% (roughly $3.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RXST expiries trade a higher absolute premium for lower per-day decay. Position sizing on RXST should anchor to the underlying notional of $5.62 per share and to the trader's directional view on RXST stock.
RXST strangle setup
The RXST strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RXST near $5.62, the first option leg uses a $5.90 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RXST chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RXST shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.90 | N/A |
| Buy 1 | Put | $5.34 | N/A |
RXST strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
RXST strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on RXST. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on RXST
Strangles on RXST are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RXST chain.
RXST thesis for this strangle
The market-implied 1-standard-deviation range for RXST extends from approximately $1.88 on the downside to $9.36 on the upside. A RXST long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RXST IV rank near 50.61% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on RXST should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RXST options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RXST-specific events.
RXST strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RXST positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RXST alongside the broader basket even when RXST-specific fundamentals are unchanged. Always rebuild the position from current RXST chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on RXST?
- A strangle on RXST is the strangle strategy applied to RXST (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RXST stock trading near $5.62, the strikes shown on this page are snapped to the nearest listed RXST chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RXST strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RXST strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 231.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RXST strangle?
- The breakeven for the RXST strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RXST market-implied 1-standard-deviation expected move is approximately 66.48%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on RXST?
- Strangles on RXST are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RXST chain.
- How does current RXST implied volatility affect this strangle?
- RXST ATM IV is at 231.90% with IV rank near 50.61%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.